Literature DB >> 12594741

MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles.

Dmitri Artemov1, Noriko Mori, Baasil Okollie, Zaver M Bhujwalla.   

Abstract

MR molecular imaging is an exciting new frontier in the biomedical applications of MR. One of the clinically relevant targets is the tyrosine kinase Her-2/neu receptor, which has a significant role in staging and treating breast cancer. In this study Her-2/neu receptors were imaged in a panel of breast cancer cells expressing different numbers of the receptors on the cell membrane. Commercially available streptavidin-conjugated superparamagnetic nanoparticles were used as targeted MR contrast agent. The nanoparticles were directed to receptors prelabeled with a biotinylated monoclonal antibody and generated strong T(2) MR contrast in Her-2/neu-expressing cells. The contrast observed in MR images was proportional to the expression level of Her-2/neu receptors determined independently with FACS analysis. In these experiments, iron oxide nanoparticles were attached to the cell surface and were not internalized into the cells, which is a major advantage for in vivo applications of the method. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12594741     DOI: 10.1002/mrm.10406

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  78 in total

1.  Off-resonance saturation MRI of superparamagnetic nanoprobes: theoretical models and experimental validations.

Authors:  Chalermchai Khemtong; Osamu Togao; Jimin Ren; Chase W Kessinger; Masaya Takahashi; A Dean Sherry; Jinming Gao
Journal:  J Magn Reson       Date:  2011-01-05       Impact factor: 2.229

Review 2.  Molecular characterization of rheumatoid arthritis with magnetic resonance imaging.

Authors:  Jeffrey T Gu; Linda Nguyen; Abhijit J Chaudhari; John D MacKenzie
Journal:  Top Magn Reson Imaging       Date:  2011-04

3.  A Novel Strategy for Surface Modification of Superparamagnetic Iron Oxide Nanoparticles for Lung Cancer Imaging.

Authors:  Gang Huang; Chunfu Zhang; Shunzi Li; Chalermchai Khemtong; Su-Geun Yang; Ruhai Tian; John D Minna; Kathlynn C Brown; Jinming Gao
Journal:  J Mater Chem       Date:  2009

Review 4.  Magnetic resonance molecular imaging with nanoparticles.

Authors:  Gregory M Lanza; Patrick M Winter; Shelton D Caruthers; Anne M Morawski; Anne H Schmieder; Katherine C Crowder; Samuel A Wickline
Journal:  J Nucl Cardiol       Date:  2004 Nov-Dec       Impact factor: 5.952

5.  Expression order of alpha-v and beta-3 integrin subunits in the N-methyl-N-nitrosourea-induced rat mammary tumor model.

Authors:  Robabeh Rezaeipoor; Eric J Chaney; Amy L Oldenburg; Stephen A Boppart
Journal:  Cancer Invest       Date:  2009-06       Impact factor: 2.176

6.  Magnetic resonance molecular imaging for non-invasive precision cancer diagnosis.

Authors:  Zheng-Rong Lu
Journal:  Curr Opin Biomed Eng       Date:  2017-11-16

7.  Multiparametric monitoring of tumor response to chemotherapy by noninvasive imaging.

Authors:  Zdravka Medarova; Leonid Rashkovetsky; Pamela Pantazopoulos; Anna Moore
Journal:  Cancer Res       Date:  2009-01-13       Impact factor: 12.701

8.  Molecular Imaging of Cancer: Applications of Magnetic Resonance Methods.

Authors:  Barjor Gimi; Arvind P Pathak; Ellen Ackerstaff; Kristine Glunde; Dmitri Artemov; Zaver M Bhujwalla
Journal:  Proc IEEE Inst Electr Electron Eng       Date:  2005-04-01       Impact factor: 10.961

9.  Molecular magnetic resonance imaging approaches used to aid in the understanding of the tissue regeneration marker Met in vivo: implications for tissue engineering.

Authors:  Rheal A Towner; Nataliya Smith; Yasuko Asano; Sabrina Doblas; Debra Saunders; Robert Silasi-Mansat; Florea Lupu
Journal:  Tissue Eng Part A       Date:  2010-02       Impact factor: 3.845

Review 10.  Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging.

Authors:  Omid Veiseh; Jonathan W Gunn; Miqin Zhang
Journal:  Adv Drug Deliv Rev       Date:  2009-11-10       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.